No direct comparison has been made between assays that quantify HBeAg.
Thus, no formal statistical comparisons are made between assays.
Our α-syn and pS129 assays typically result in inter-plate variability <15% and intra-plate variability <10% [ 17, 28]; no corrections were made for assays that performed within this range.
The value of the lumped constant, the factor that converts DG phosphorylation into glucose phosphorylation, is relatively stable when glucose levels are within or above the normoglycaemic range, but appropriate corrections must be made when assays are carried out under hypoglycaemic or other abnormal conditions.
Fifth, no clinically relevant cut-points have been established for endothelial activation biomarkers, and assays are not standardized between laboratories, making direct comparisons between studies difficult to interpret.
Radical statements need to be me made by manufacturers that assays are not suitable for early pregnancy and not appropriate for monitoring cancer and gestational trophoblastic disease.
All assays are made publicly accessible through websites such as PeptideAtlas and SRMAtlas.
Advances in assays have made C-peptide measurement both more reliable and inexpensive.
Crucially, it contributes to inter-lab reproducibility if assays are made robust enough to be transferred.
7, 40, 41 Two additional clinical decision-making assays, the Oncotype DX 21-gene assay 42 (Genomic Health, Inc. (Redwood City, CA, USA) and a clinically updated version of the intrinsic subtype PAM50 assay 43 (ARUP Laboratories, Salt Lake City, UT, USA), have been compared.
